RLY ETF

Relay Therapeutics, Inc. reported positive interim data from its phase 1 ReDiscover study, using RLY-2608 + fulvestrant for treatment of PI3Ka-mutated HR+/HER2- locally advanced or metastatic breast cancer patients. Key upcoming milestones for RLY-2608 program includes presenting data at the San Antonio Breast Cancer Symposium in December 2024 and initiating a phase 3 study in 2025. Expansion opportunities of the RLY-2608 program includes two triplet regimens targeting 1st-line PI3Ka-mutant HR+/HER2- breast cancer patients and phase 1 study for tumors with vascular formations starting in Q1 2025.

Relay Therapeutics' Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets PI3Kα-mutated HR+/HER2- breast cancer, with promising Phase 2 results and potential approval by 2026-2027. The company's RLY-4008 targets FGFR2-altered cholangiocarcinoma, and it is seeking pivotal trials and a commercialization partner to unlock broader market potential.

Interim data to be reported for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Conference call to be held Monday, September 9, at 8am ET CAMBRIDGE, Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced plans to host a conference call and webcast to report data for RLY-2608 600mg BID + fulvestrant in the ongoing ReDiscover trial in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer and next steps on Monday, September 9, 2024, at 8:00 a.m.

Asset allocation is still important despite recent performance trends. SPDR® SSgA Multi-Asset Real Return ETF offers a mix of asset class exposure for real returns. The RLY ETF focuses on inflation-protected securities, real estate securities, commodities, and infrastructure companies.

SPDR® SSgA Multi-Asset Real Return ETF is an actively managed fund of funds aiming at excess return over inflation. The RLY fund provides exposure to inflation-protected securities, real estate securities, commodities, infrastructure companies, and natural resources and commodity businesses. Performance and risk metrics since 2012 are underwhelming, but RLY has outperformed other multi-asset ETFs in the inflationary environment of the last 3 years.